Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Decreases By 46.4%

Xenetic Biosciences Inc (NASDAQ:XBIO) was the target of a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 4,500 shares, a decline of 46.4% from the February 28th total of 8,400 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average trading volume of 7,100 shares, the short-interest ratio is presently 0.6 days.

Xenetic Biosciences Price Performance

Shares of XBIO stock opened at $3.30 on Friday. The stock has a market capitalization of $5.08 million, a price-to-earnings ratio of -1.24 and a beta of 2.17. The company’s fifty day simple moving average is $3.91 and its two-hundred day simple moving average is $3.98. Xenetic Biosciences has a 1 year low of $2.78 and a 1 year high of $5.20.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.48). The company had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.18 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. Equities research analysts anticipate that Xenetic Biosciences will post -1.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “neutral” rating on shares of Xenetic Biosciences in a research report on Thursday, March 20th.

Institutional Investors Weigh In On Xenetic Biosciences

An institutional investor recently raised its position in Xenetic Biosciences stock. Renaissance Technologies LLC lifted its position in Xenetic Biosciences Inc (NASDAQ:XBIO) by 61.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 25,550 shares of the company’s stock after purchasing an additional 9,700 shares during the quarter. Renaissance Technologies LLC owned about 1.66% of Xenetic Biosciences worth $102,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.